How Did OncoSil Navigate Disclosure of PANCOSIL Trial Results at CIRSE?

Context of Disclosure

OncoSil Medical Limited (ASX – OSL) has responded comprehensively to ASX queries regarding the timing and compliance of its disclosure of the PANCOSIL Phase 1-2 clinical trial results. The trial, conducted by Amsterdam University Medical Centre (Amsterdam UMC), evaluates the safety and feasibility of OncoSil’s radionuclide therapy device in treating unresectable locally advanced pancreatic cancer.

The preliminary results were first publicly presented by Dr. Danielle Vos at the Cardiovascular and Interventional Radiological Society of Europe (CIRSE) Congress in Barcelona on 16 September 2025. OncoSil confirmed it only became aware of the data at the time of this presentation, as the trial data remained confidential and under Amsterdam UMC’s control until then.

Compliance with ASX Continuous Disclosure Rules

Following the CIRSE presentation, OncoSil promptly requested a trading halt on 17 September to allow management to analyze the results and prepare an informed market announcement. The company’s board approved the release of the announcement on 18 September, which was then issued on the ASX Market Announcements Platform (MAP) pre-open.

OncoSil emphasized that it had no prior access to the trial data and was therefore unable to disclose the information earlier. The company also confirmed its adherence to ASX Listing Rules 3.1 and 15.7, which govern timely disclosure of material information and prohibit market release before ASX acknowledgment.

Details of the PANCOSIL Trial Presentation

Dr. Vos’s presentation covered the current treatment landscape for pancreatic cancer, the OncoSil device’s mechanism and administration methods, and the design and purpose of the PANCOSIL trial. Key preliminary findings highlighted included a 10% rate of serious adverse events related to the procedure or device within 90 days, a 90% feasibility rate for tumor puncture and device injection, and early signals of tumor response attributable solely to the OncoSil device.

While OncoSil provided ASX with images from the presentation, contractual obligations with Amsterdam UMC prevent full public release of the presentation materials.

Looking Ahead

OncoSil’s transparent handling of the disclosure process underscores its commitment to regulatory compliance and investor communication. The company’s continuous disclosure policy and board oversight mechanisms remain in place to manage future announcements.

Investors will be watching closely for further clinical data releases and how these preliminary results translate into commercial and regulatory milestones for OncoSil’s pancreatic cancer therapy.